<DOC>
	<DOC>NCT00788541</DOC>
	<brief_summary>The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Clinical diagnosis of OpenAngle Glaucoma or Ocular Hypertension for at least 6 months; Other protocoldefined inclusion criteria may apply. Prior angle surgery in the study eye, severe visual field loss in either eye; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Intraocular Pressure</keyword>
	<keyword>Anecortave Acetate</keyword>
</DOC>